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Abstract—In response to an inflammatory stimulus, arachidonic acid (AA), the main polyunsaturated fatty
acid present in the phospholipid layer of cell membranes, is released and metabolized to a series of
eicosanoids. These bioactive lipid mediators of inflammation arise physiologically through the action of
the enzymes 5-lipoxygenase (5-LOX) and cyclooxygenases (constitutive COX-1 and inducible COX-2). It is
believed that dual inhibition of 5-LOX and COXs may have a higher beneficial impact in the treatment of
inflammatory disorders rather than the inhibition of each enzyme.With this demand for new dual-acting anti-
inflammatory agents, a range of 2,3-diarylxanthones were tested through their ability to interact in the AA
metabolism. In vitro anti-inflammatory activity was evaluated through the inhibition of 5-LOX-catalyzed
leukotriene B4 (LTB4) formation in human neutrophils and inhibition of COX-1- and COX-2-catalyzed
prostaglandin E2 (PGE2) formation in human whole blood. The results showed that some of the studied
arylxanthones were able to prevent LTB4 production in human neutrophils, in a concentration-dependent
manner. The xanthone with a 2-catechol was the most active one (IC50 ∼ 9 μM). The more effective
arylxanthones in preventing COX-1-catalyzed PGE2 production presented IC50 values from 1 to 7 μM,
exhibiting a structural feature with at least one non-substituted aryl group. All the studied arylxanthones were
ineffective to prevent the formation of PGE2 catalyzed by COX-2, up to the maximum concentration of
100 μM. The ability of the tested 2,3-diarylxanthones to interact with both 5-LOX and COX-1 pathways
constitutes an important step in the research of novel dual-acting anti-inflammatory drugs.
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INTRODUCTION
Inflammation is the natural response of the organism
to tissue damage, most of the times arising from physical or
chemical irritations, infections caused by a pathogen, or
other injuries. It is also part of a complex physiological
protective response to harmful stimuli in a body’s attempt
to heal itself, through the elimination of the initial cause of
cell injury, removing necrotic cells and tissues, and initiat-
ing the process of repair. The inflammatory response is
induced by chemical mediators produced locally by dam-
aged cells at the site of inflammation or derived from
circulating inactive precursors (typically synthesized by
the liver) that are activated at the referred site [1]. There
are two types of chemical mediators: cell-derived media-
tors that include histamine and serotonin (preformed me-
diators in secretory granules) and mediators synthesized as
needed such as arachidonic acid (AA) metabolites (leuko-
trienes, prostaglandins, and platelet-activating factor), cy-
tokines, and nitric oxide; and plasma-derived mediators
which include complement activation system, kinin
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system, and coagulation/fibrinolysis system [2]. These me-
diators are involved in the activation of resident cells such
as endothelial and epithelial cells and/or the recruitment
and activation of inflammatory cells such as macrophages,
monocytes, and neutrophils [1]. Two of these proinflam-
matory mediators are leukotrienes and prostaglandins that
arise via arachidonic acid metabolism. The first step is the
hydrolysis of this 20-carbon polyunsaturated fatty acid
present in the phospholipid layer of cell membranes, cata-
lyzed by the enzyme phospholipase A2. Then, free AA can
be metabolized by several lipoxygenases (LOXs), leading
to the formation of a series of hydroxy acids and leukotri-
enes. In mammalian tissues, 5-LOX is generally found in
cells of myeloid origin, like polymorphonuclear leuko-
cytes, activated macrophages, and mast cells, and it is the
main enzyme implicated in inflammatory and allergic dis-
orders. The metabolism of AA can also involve the forma-
tion of prostaglandins through the action of membrane
protein cyclooxygenase (COX, also known as prostaglan-
din H synthase). Two isoforms of COX are implicated in
the inflammatory process: COX-1, which is constitutively
expressed within most tissues and responsible for the nor-
mal physiological production of prostaglandins, and COX-
2, that although absent in most normal tissues is highly
induced by several inflammatory andmitogenic cells and is
responsible for the overproduction of prostaglandins dur-
ing inflammation [3].
Non-steroidal anti-inflammatory drugs (NSAIDs) are
among the most common medicines used to restrain the
characteristic signs of an inflammatory process. Nonethe-
less, drawbacks such as gastrointestinal disorders and renal
damage limit their use. An alternative strategy is the use of
selective COX-2 inhibitors that decreases these effects but
is associated to cardiac implications [4]. Thus, many efforts
have been made in order to develop the so-called dual-
acting anti-inflammatory drugs able to inhibit both 5-LOX
and COXs, maintaining the activity of classical NSAIDs
while avoiding their side effects [5, 6].
Xanthones (9H-xanthen-9-ones) are an important
class of oxygenated heterocyclic compounds widespread
in nature. The pharmacological properties of both natural
and synthetic xanthones (e.g., anti-inflammatory, antima-
larial, antioxidant, and antitumour activities) are associated
to different substituents in different positions of their main
core [7–12]. Aryl groups linked to xanthones are scarce in
natural sources, but several publications reporting their
synthesis and/or biomedical potential have been highlight-
ed in literature and reviewed in [13]. In fact, the hydroxyl-
ated 2,3-diarylxanthones studied in the present work were
already described as capable of scavenging oxygen and
nitrogen reactive species [14, 15] and inhibiting lipid per-
oxidation [16]. As so, they can be seen as excellent candi-
dates to act as modulators of the inflammatory process. The
present investigation was undertaken to evaluate the inter-
action of a range of 2,3-diarylxanthones in the AA metab-
olism regarding their interference in the 5-LOX enzyme
activity, namely through the inhibition of leukotriene B4
(LTB4) production in human neutrophils, and COX-1 and
COX-2 enzyme activities, specifically through the inhibi-
tion of prostaglandin E2 (PGE2) production in human
whole blood.
MATERIAL AND METHODS
Reagents, Chemicals, and Equipment
All chemicals and solvents used were of analytical
grade, obtained from commercial sources, and used as re-
ceived. Acetylsalicylic acid, arachidonic acid (AA), calcium
ionophore (A23187), chremophor® EL, dimethyl sulfoxide
(DMSO), gentamicin sulfate, Hank’s balanced salt solution
(HBSS), lipopolysaccharides from Escherichia coli 026:B6
(LPS), methanol, nordihydroguaiaretic acid (NDGA), and
trypan blue solution 0.4% were obtained from Sigma-
Aldrich Co. LLC (St. Louis, USA). The thromboxane syn-
thase inhibitor (TXBSI) was synthesized as previously de-
scribed [17]. The BLeukotriene B4 Enzyme Immunoassay
(EIA) Kit^ was obtained from Cayman Chemical (Ann Ar-
bor, MI). The BPGE2 EIAKit^ was obtained from Enzo Life
Sciences (Lausen, Switzerland). 2,3-Diarylxanthones 1–3
(Fig. 1) were synthesized according to a previously described
procedure [18].
A multimode microplate reader (Synergy HT, BIO-
TEK) with temperature control capacity was used to per-
form the spectrophotometric readings in all the assays.
5-LOX—Neutrophil Assay
Isolation and Treatment of Human Neutrophils
Following informed consent, neutrophils were isolat-
ed from venous blood collected from healthy human vol-
unteers, by antecubital venipuncture, into K3EDTA vacu-
um tubes. The isolation of the human neutrophils was
performed by the density gradient centrifugation method
as previously described [19]. Cell viability and cell yield
were evaluated by the trypan blue exclusion method, using
a Neubauer chamber and an optic microscope with ×40
magnification. HBSS was used as the incubation medium
and the isolated neutrophils’ suspensions were kept on ice
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until use. Neutrophils’ suspensions (3.5 × 106 cells/mL) in
HBSS were placed in 96-well microplates (140 μL/well) at
37 °C for 10 min to equilibrate. The tested xanthones (1.0–
20 μM), dissolved in a (9:1) mixture of HBSS:DMSO,
were then added and pre-incubated for 10 min. The cells
were subsequently incubated with A23187 (5 μM) and AA
(10 μg/mL) for 8 min. The reactions were stopped by the
addition of cold methanol. Samples were subsequently
centrifuged at 13,000×g for 5 min at 4 °C and the super-
natants were collected and stored at −20 °C until use [20].
The quantity of solvents used did not have inhibitory
effects and neither affected the cellular viability.
Determination of LTB4 Production in Human Neutrophils
The amount of LTB4 in the collected supernatants was
measured using the above mentioned commercial EIA kit,
according to the manufacturer’s instructions. The 5-LOX
inhibitor, NDGA (1 μM), was used as positive control. The
results were expressed as the percent inhibition of control
LTB4 production. At least three independent experiments
were performed to each assay.
COXs—Human Whole-Blood Assay
COX-1 Assay
Following informed consent, venous blood was col-
lected from healthy human volunteers, by antecubital ve-
nipuncture, into heparin-Li+ vacuum tubes. The human
whole-blood assay to assess the COX-1 inhibition was
performed as previously reported [21, 22]. Collected blood
(500 μL) was placed in microtubes and incubated in a
water bath at 37 °C with TXBSI (1 μM) and the tested
xanthones (0.312–100 μM) dissolved in DMSO for
15 min. Then, the A23187 (12.2 μg/mL) was added and
the mixture was incubated for 15 min, allowing the trig-
gering of COX-1 activity. The reactions were stopped
putting the samples on ice for 5 min, followed by centri-
fugation at 1000×g for 20 min at 4 °C. The supernatants
were then collected and stored at −20 °C until use. The
quantity of solvents used did not have inhibitory effects
and neither affected the cellular viability.
COX-2 Assay
The human whole-blood assay to assess the COX-2
inhibition was performed as previously described, with
modifications [22, 23]. Collected blood (800 μL) was
placed in six-well plates and incubated for 15 min in a
humidified incubator at 37 °C with TXBSI (1 μM),
acetylsalicylic acid (10 μg/mL), and the tested xanthones
(1–100 μM), dissolved in a (1:10) mixture of
DMSO:(chremophor/ethanol 1%). Here, TXBSI reduces
the amount of LPS needed and its incubation period. Then,
LPS (10 μg/mL) was added and the mixture was incubated
for 5 h, allowing the activation of COX-2. The reactions
were stopped by adding DPBS-gentamicin buffer (1 mL)
to the samples and placing them on ice for 10 min. Subse-
quently, the samples were centrifuged at 1000×g for
15 min at 4 °C and the supernatants were collected and
stored at −20 °C until use. The quantity of solvents used
did not have inhibitory effects and neither affected the
cellular viability.
Determination of PGE2 Production in Human Whole
Blood
The amount of PGE2 in the samples (thawed plasma
supernatants) was measured using the above mentioned
commercial EIA kit, according to the manufacturer’s in-
structions, as an indicator of COX-1 and COX-2 activities.
Indomethacin (1 μM) and celecoxib (10 μM) were used as
positive controls for COX-1 and COX-2 assays, respec-
tively. The results were expressed as the percent inhibition
of control PGE2 production. At least three independent
experiments were performed to each assay.
Statistical Analysis
Statistical analyses were calculated using the
GraphPad Prism 6 software (GraphPad Inc., La Jolla,
Fig. 1. Chemical structures of the tested 2,3-diarylxanthones 1–3.
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CA). The results were expressed as the percent inhibition
of control LTB4 production [mean ± standard error of the
mean (SEM)]. IC50 values were calculated from the curves
of percent inhibition of control LTB4 production or PGE2
production versus compound concentration. Statistical
comparison between groups was estimated using the one-
way analysis of variance (ANOVA), followed by the
Bonferroni post hoc test. In all cases, p values lower than
0.05 were considered as statistically significant.
RESULTS
Inhibition of LTB4 Production in Human Neutrophils
All the tested xanthones were able to inhibit the 5-
LOX–LTB4 production induced by A23187 and AA in
human neutrophils, in a concentration-dependent manner
(Fig. 2). It was only possible to calculate the IC50 value for
the most active compounds, and regarding these results, the
order of potencies found was as follows: 1c (9.2 ± 4.1 μM),
1b (11.6 ± 4.6 μM), 3a (13.5 ± 0.6 μM), and 3b (13.7 ±
2.1 μM) (Table 1).
At 20μM, the highest tested concentration, xanthones
1b and 3b exhibited higher inhibitory rates of 71.1 ± 6.8
and 68.5 ± 5.8%, respectively. Xanthones 1c and 3a were
also quite active with percentages of inhibition of 62.9 ±
5.8 and 60.7 ± 2.6%, respectively, for 20 μM. The other
tested xanthones presented activities lower than 50% up to
20 μM.
Overall, from compounds of group 1, at 20 μM con-
centration, derivative 1b (71.1 ± 6.8%) was the most active,
followed by 1c (62.9 ± 5.8%) and 1a (40.5 ± 6.9% of inhibi-
tion). All xanthones from group 2 were generally less active
than the other tested xanthones, being derivative 2c the best
of its group (60.7 ± 2.6% of inhibition). From group 3, xan-
thone 3b (68.5 ± 5.8%) was the most active one, followed by
3a (60.7 ± 2.6%) and 3c (46.7 ± 1.2% of inhibition).
NDGA was used as positive control and showed an
inhibitory activity of 47.7 ± 3.5%, for a concentration of
1 μM (Table 1).
Inhibition of PGE2 Production in HumanWhole Blood
In what concerns inhibition of COX-1–PGE2 produc-
tion stimulated by A23187, the most active compounds
were compounds 2a, 1a, and 1b (IC50 = 0.8 ± 0.2, 1.7 ± 0.4,
and 2.8 ± 0.4 μM, respectively) (Table 1). Compounds 3a,
2b, and 1c were also effective inhibitors with IC50 values of
6.6 ± 1.1, 15.8 ± 3.3, and 29.5 ± 4.7 μM, respectively.
The results in terms of percentage of inhibition, to
10 μM concentration, are in accordance with the IC50
values found. Thus, it is possible to establish two groups
from the studied xanthones (Fig. 3). The first group in-
cludes the most active compounds, with inhibitory effects
higher than 50% (for a concentration of 10 μM), in the
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Fig. 2. Inhibition of LTB4 production induced by A23187 and AA in human neutrophils by the tested xanthones 1–3, determined by EIA. Each value
represents the mean ± SEM of at least three experiments. ****P< 0.0001, **P< 0.01, compared to the stimulated control (A23187/AA).
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following order of potencies: 1a (91.4 ± 2.1%) > 2a (89.7
± 6.1%) > 1b (78.8 ± 7.1%) > 3a (65.8 ± 6.8%). In the
second one are placed the xanthones with activities lower
than 50%, for 10 μM concentration. Compounds 2b (38.2
± 4.9%) and 1c (22.1 ± 7.2%) were the most active of this
second group, being the other derivatives ineffective to
inhibit the COX-1–PGE2 production at this concentration.
Nevertheless, xanthones 3b and 3c showed an inhibitory
Table 1. Inhibitory Effects (IC50 μM, mean ± SEM) of the Studied Xanthones 1–3 on the 5-LOX–LTB4 Production in Human Neutrophils and COX-1–
PGE2 Production in Human Whole Blood. Each Study Corresponds to at Least Three Experiments
Compounds R1 R2 IC50 (μM) ± SEM5-LOX COX-1
1a H H ND 1.7 ± 0.4
1b OH H 11.6 ± 4.6 2.8 ± 0.4
1c OH OH 9.2 ± 4.1 29.5 ± 4.7
2a H H ND 0.8 ± 0.2
2b OH H ND 15.8 ± 3.3
2c OH OH ND ND
3a H H 13.5 ± 0.6 6.6 ± 1.1
3b OH H 13.7 ± 2.1 ND
3c OH OH ND ND
Positive controls
NDGA 47.7 ± 3.5
1μM*
ND
Indomethacin ND 89.7 ± 2.4
1μM*
ND not determined
aThe values represent the percentage of inhibition ± SEM for the highest tested concentration (in superscript)
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Fig. 3. Inhibition of COX-1 PGE2 production induced by A23187 in human whole blood by the xanthones 1–3 determined by EIA. Each value represents
mean ± SEM of at least three experiments. ****P< 0.0001, *P< 0.1, compared to the stimulated control (TXBSI/A23187).
960 Santos, Ribeiro, Silva, and Fernandes
activity of 43.7 ± 7.2 and 37.1 ± 8.5%, respectively, for
100 μM, the highest tested concentration (Fig. 3).
Overall, among all the tested compounds, in a 10 μM
concentration, xanthones of group 1 were generally more
active than the corresponding xanthones from the other
groups, derivative 1a being the best of its group (91.4 ±
2.1% inhibition). From group 2, xanthone 2awas the most
active one (89.7 ± 6.1% inhibition), followed by 2b (38.2
± 4.9% inhibition), whereas 2c was not active, up to the
highest tested concentration, 100 μM. Xanthone 3a (65.8
± 6.8% inhibition) was the only effective inhibitor from
group 3, the less active group of all the studied xanthones
(Fig. 3). Indomethacin was used as positive control and
showed an inhibitory activity of 89.7 ± 2.4%, for a concen-
tration of 1 μM (Table 1).
None of the studied xanthones 1–3 were able to
inhibit COX-2–PGE2 production induced by LPS in hu-
man whole blood, up to the highest tested concentration,
100 μM. Selective COX-2 inhibitor celecoxib (10 μM)
reached a 75.4 ± 7.2% inhibitory effect.
DISCUSSION
The inhibition of 5-LOX pathway by the studied 2,3-
diarylxanthones 1–3 are reported here for the first time. All
the studied compounds proved to be effective inhibitors of
LTB4 production induced by A23187 and AA in human
neutrophils at the concentration of 20 μM (in a range of
inhibition from 36 to 71%). Generally, compounds of
group 1 (non-substituted 3-phenyl ring) were the most
active inhibitors while compounds of group 2 were the less
active ones (possessing a 3-phenol group). An important
structural feature for the higher inhibitory effect seems to
be the presence of 2- or 3-catechol groups. Xanthone 1c
(substituted with 2-catechol group and non-substituted 3-
phenyl ring) presented an IC50 value of around 9 μM. In
fact, the presence of a catechol moiety in a wide variety of
flavonoids has been described as vital for the inhibition of
prooxidant enzymes like LOX [24, 25]. Moreover, Sadik
et al. also pointed out that the inhibitory effect on 15-LOX
enzyme by several flavonoids possessing a catechol unit
correlates inversely with the number of other hydroxy
groups in their skeleton [25]. The excessive number of
hydroxy groups lowers the hydrophobicity of the com-
pound and restrains their access to the active site of the
enzyme. This feature can be an explanation for the lower
inhibitory activity of compound 3c (the highly substituted
tested xanthone) when compared to the other xanthones of
group 3.
Few studies have highlighted the potential anti-
inflammatory action of a range of xanthones; however, it
is a hard task to make a comparison of results since differ-
ent experimental conditions and enzyme sources are used.
As examples of studies with natural xanthones, 1,3,6,7-
tetrahydroxyxanthone, a mangiferin aglycone known as
norathyriol 4a (Fig. 4), suppressed A23187-induced
LTB4 formation in rat neutrophils (IC50 = 2.3 ± 0.2 μM)
and in blood taken from pretreated mice to about 20% of
corresponding control values [26]. Aqueous extract of
Mangifera indica L. and the glucosylxanthone mangiferin
4b (Fig. 2) isolated from this extract have also been tested
for the A23187-induced LTB4 release in J774 murine
macrophage [27] and RAW264.7 macrophage [28] cell
lines. The purified compound showed a higher inhibitory
effect (IC50 = 2.1 μg/mL) than the extract (IC50 = 26.0 μg/
mL) for J774 murine macrophages whereas mangiferin 4b
at 10 μg/mL presented 68.8% of inhibition and the extract
at 10 μg/mL showed 41.0% of inhibition of LTB4 produc-
tion, for RAW264.7 macrophages. Crockett et al. isolated a
furanoxanthone 5 (Fig. 4) from the roots of Hypericum
perforatum and evaluated the inhibition of 5-LOX-
catalyzed LTB4 formation in polymorphonuclear leuko-
cytes. The results indicated an inhibition of 98.46 ±
0.59% at 50μg/mL (146μM) and an IC50 of 10.2μM [29].
Several mechanisms can be associated to the inhibi-
tion of LTB4 production by flavonoids and phenolic com-
pounds. It can include the inhibition of the enzyme phos-
pholipase A2 and consequently the release of AA, the
inhibition of enzyme LTA4 hydrolase, the blockade of 5-
lipoxygenase-activating protein for leukotriene biosynthe-
sis, and even direct inhibition of 5-LOX [20]. Werz and
Steinhilber proposed that LOX inhibitors can be divided
into redox-active compounds, iron-ligand inhibitors with
weak redox-active properties, and non-redox-type inhibi-
tors [30]. Examples of redox-active compounds are
NGDA, coumarins, and flavonoids, but unfortunately, the
former ones presented lack of selectivity in most cases and
were rapidly metabolized. Hydroxamic acid and N-hy-
droxyurea derivatives act as iron-chelating inhibitors, but
their hydroxamate group is easily metabolized in vivo and
showed unfavorable pharmacokinetic properties. The clas-
sification of non-redox-type inhibitors is associated to the
lack of redox activity of the drugs themselves but does not
exclude that their inhibitory effect is influenced by the
redox state of the target 5-LOX. Several compounds tested
by oral administration proved to be selective to inhibit
leukotriene biosynthesis in human leukocytes and whole
blood but without success to inhibit their synthesis at sites
of chronic inflammation [24, 30]. As far as we know, no
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mechanism underlying the effect of xanthones on 5-LOX
pathway has been proposed. We can presume that similar
to phenolic compounds, xanthones act as redox 5-LOX
inhibitors. In fact, this type of 5-LOX inhibition is pointed
to the hydroxyxanthone norathyriol 4a by the results of
inhibition of human recombinant 5-LOX activity in a cell-
free system [26]. Previous studies suggested that phenolic
inhibitors can act at the 5-LOX catalytic domain by reduc-
ing the active iron from catalytically active Fe(III) to the
inactive Fe(II) form [31] or by modulation of the hydro-
peroxide tone [32].
The results from the COX assays showed that the
studied 2,3-diarylxanthones were only able to inhibit the
COX-1–PGE2 production stimulated by A23187 in human
whole blood, in a concentration-dependent manner, except
compound 2c that was not active up to 100 μM, the highest
tested concentration. The most effective inhibitors in each
group of xanthones tested were those non-substituted in ring
D, specifically 1a, 2a, and 3a with IC50 values from 1 to
7 μM. Similar to the results of 5-LOX inhibition, increasing
the number of hydroxy groups seems to be disadvantageous
in preventing the production of PGE2 catalyzed by COX-1.
Indeed, xanthones 2c (not active) and 3b (holding three
hydroxy groups) and xanthone 3c (with four hydroxy
groups) did not reach an IC50 at all. These data are corrob-
orated by Ribeiro et al. that previously found in structural-
similar compounds, the less substituted flavonoids were
those presenting a higher inhibitory activity [22].
This is the first paper that reports the inhibition of
COX-1 activity by 2,3-diarylxanthones, but there are a few
studies that explore the inhibitory capacity of other
substituted xanthones using different experimental condi-
tions. Thus, Hsu et al. tested the inhibitory effect of ram
seminal vesicle COX-1 activity in a range of 18 mono, di,
tri, and tetraoxygenated xanthones [26]. Norathyriol 4a
(Fig. 4) was the most active compound (IC50 = 16.2 ±
1.5 μM), with even higher inhibitory potency than the
other three tetrahydroxyxanthones tested. Mono, di, and
trihydroxyxanthones were less active than norathyriol, at
least with fourfold lower potency. From this study, we can
also state that norathyriol 4a showed a similar inhibition of
COX-1 and COX-2 activities and a higher efficiency to
inhibit human recombinant 5-LOX [26]. The inhibition of
ram seminal vesicle COX-1 activity was also examined for
furanochromone 5 [29] and trihydroxylated xanthone 6,
isolated from the bulbs of Ledebouria ovatifolia [33]
(Fig. 4). These compounds displayed minor inhibitory
effects of 18.41 ± 6.50% at 50 μg/mL (146 μM) and 44
± 11% at 10 μM, respectively, although xanthone 6 was
selective for COX-2 at 10 μM. γ-Mangostin 7c, a xan-
thone present in the fruit hull of mangosteen, and its related
compound patulone 8 exhibited a similar effect but in
higher extent than garcinone B 9 (Fig. 4) on PGE2 release
stimulated by A23187 in C6 rat glioma cells [34, 35]. The
in vitro enzyme assays showed that γ-mangostin 7a
prevented, in a concentration-dependent manner, both
COX-1 (IC50 = 0.8 μM) and COX-2 (IC50 = 2 μM) activ-
ities [34] as well as patulone 8 (Fig. 4) had the ability to
prevent the enzymatic activity of COX-1 [35].
Although none of the studied 2,3-arylxanthones 1–3
were able to prevent the COX-2–PGE2 production stimu-
lated by LPS in human whole blood, there are several
reports highlighting the preventive effects of several xan-
thones against COX-2 activity. Garrido et al. studied the
LPS-interferon gamma-induced PGE2 release by
mangiferin 4b in J774 murine macrophage cell lines that
Fig. 4. Chemical structures of xanthones already studied in LOX and COX assays.
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showed a high inhibitory activity with an IC50 value of
17.2 μg/mL [27]. Using RAW264.7 macrophage cells, the
inhibitory potency of α-mangostin 7a (IC50 = 13.9 μg/mL)
and γ-mangostin 7c (IC50 = 13.5 μg/mL) was also very
significant [36] while β-mangostin 7b proved to be a
selective inhibitor of COX-2 (53.0 ± 6.0% inhibition at
20 μg/mL), with a slight effect on COX-1 activity (17.1
± 1.0% inhibition at 20 μg/mL) [37]. A similar behavior
was observed for furanoxanthone 5 tested in a concentra-
tion of 50 μg/mL where the results pointed to a moderate
inhibition of COX-2 activity (36.15 ± 4.68%) and a slight
inhibition of COX-1 activity (18.41 ± 6.50%) [29]. This
short results seem to indicate that xanthones bearing oxy-
genated substituents and lipophilic carbon chains are good
candidates as COX-2 inhibitors.
CONCLUSION
In this study, for the first time, a range of 2,3-
diarylxanthones showed to suppress LTB4 production induced
by A23187 and AA in human neutrophils, in a concentration-
dependent manner. The results point out to an inhibition in a
range of 36 to 71%, at 20 μM, the highest tested concentra-
tion. The most active one was xanthone 1c with a 2-catechol
group presenting an IC50 value around 9 μM.
The 2,3-diarylxanthones were also tested for their abil-
ity to inhibit PGE2 production stimulated by A23187 and
LPS in human whole blood. At 10 μM concentration,
xanthones 1a, 1b, 2a, and 3a (possessing at least one non-
substituted aryl group) exhibited COX-1 inhibitory effects
higher than 50% and with IC50 values from 1 to 7 μM. The
COX-2 activity was unaffected by the 2,3-diarylxanthones,
up to the highest tested concentration, 100 μM. In conclu-
sion, the 2,3-diarylxanthones studied had a dual impact on
the 5-LOX and COX-1 activities, an important contribution
to reinforce the potential of this class of heterocyclic com-
pounds in the modulation of the production of inflammatory
mediators and it challenges to pursuit for novel structures
with improved selectivity in the inflammatory cascade.
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